Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes

被引:27
|
作者
Nicolucci, Antonio [1 ]
Ceriello, Antonio [2 ,3 ]
Di Bartolo, Paolo [4 ]
Corcos, Antonella [5 ]
Orsini Federici, Marco [5 ]
机构
[1] Ctr Outcomes Res & Clin Epidemiol CORES, Pescara, Italy
[2] Inst Invest Biomed August Pi & Sunyer DIBAPS, Barcelona, Spain
[3] IRCCS MultiMed, Milan, Italy
[4] Internist Ravenna AUSL Romagna, Direttore UO Diabetol, Rete Clin Diabetol Aziendale Dipartimento, Ravenna, Italy
[5] Eli Lilly Italia SpA, Med Affairs Diabet, Sesto Fiorentino, Italy
关键词
Diabetes; Glycemic variability; Meta-analysis; Rapid-acting insulin analogues; Regular human insulin; BLOOD-GLUCOSE CONTROL; HUMAN SOLUBLE INSULIN; HUMAN PREMIX INSULIN; PLASMA-GLUCOSE; NOCTURNAL HYPOGLYCEMIA; INTENSIVE THERAPY; LISPRO INSULIN; NPH INSULIN; TYPE-1; ASPART;
D O I
10.1007/s13300-019-00732-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The aim of this meta-analysis was to investigate the impact of rapid-acting insulin analogues (RAIAs) and regular human insulin (RHI) on glycemic control, including long- and short-term glycemic variability as measured by glycated haemoglobin (HbA1c) and pre- and postprandial glucose (PPG). Methods PubMed was searched for studies published between 1999 and 29 June 2016. Randomised controlled trials of patients with diabetes that assessed the effects of RAIAs or RHI on glycemic control, focusing on preprandial glucose, PPG and HbA1c, were included. Only studies that reported both means and standard deviations for those outcomes were analysed; from these data, weighted mean differences and 95% confidence intervals were generated to yield overall point estimates. The primary outcomes of the meta-analysis were the mean differences between RAIAs and RHI at the end of the study in PPG, preprandial glucose, and HbA1c. Results Twenty-seven studies (n = 7452) were included. The difference in PPG between RAIA- and RHI-treated patients was significant-in favour of RAIAs-in patients with type 1 diabetes (T1D) [- 22.2 mg/dL; 95% confidence interval (CI) - 27.4, - 17.0 mg/dL; P < 0.0001] but not in those with type 2 diabetes (T2D). For preprandial glucose, there was a non-significant trend favouring RHIs in T1D; no data were available for patients with T2D. In patients with T1D, the between-group difference in end-of-treatment (EOT) HbA1c favoured RAIAs (- 0.13%; 95% CI - 0.18, - 0.08%; P < 0.0001), but was not significant in patients with T2D. The main study limitations were the small number and heterogeneity of the included studies. Conclusions These results demonstrate that RAIAs are more effective at reducing PPG and improving HbA1c than RHIs in T1D. More data are required to assess the effect of these agents on glucose control in T2D. Plain Language Summary Plain language summary available for this article.
引用
收藏
页码:573 / 584
页数:12
相关论文
共 50 条
  • [31] SAFETY AND EFFECTIVENESS OF INSULIN ANALOGUES VERSUS HUMAN INSULIN IN TYPE 2 DIABETES; A SYSTEMATIC REVIEW AND META-ANALYSIS
    Davari, M.
    Amani, B.
    Gharibnaseri, Z.
    Dehghani, M.
    Zakeri, H.
    Khorasan, E.
    Varmaghani, M.
    VALUE IN HEALTH, 2017, 20 (09) : A474 - A474
  • [32] Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus
    Plank, J
    Siebenhofer, A
    Berghold, A
    Jeitler, K
    Horvath, K
    Mrak, P
    Pieber, TR
    ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (12) : 1337 - 1344
  • [33] Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes
    Davidson, Mayer B.
    ANNALS OF INTERNAL MEDICINE, 2019, 170 (08) : JC39 - JC39
  • [34] Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections
    Bode, Bruce W.
    CLINICAL THERAPEUTICS, 2007, 29 : S135 - S144
  • [35] Glycemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with type 2 diabetes
    Dailey, G
    Rosenstock, J
    Moses, R
    Ways, K
    DIABETES, 2004, 53 : A121 - A121
  • [36] Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type2 diabetes mellitus
    Kuroda, Akio
    Kaneto, Hideaki
    Kawashima, Satoshi
    Sakamoto, Kenya
    Takahara, Mitsuyoshi
    Shiraiwa, Toshihiko
    Yasuda, Tetsuyuki
    Katakami, Naoto
    Matsuoka, Taka-aki
    Shimomura, Iichiro
    Matsuhisa, Munehide
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (01): : 78 - 81
  • [37] Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes
    Luijf, Yoeri M.
    van Bon, Arianne C.
    Hoekstra, Joost B.
    DeVries, J. Hans
    DIABETES CARE, 2010, 33 (10) : 2152 - 2155
  • [38] Effects of Long Acting Insulin Versus Rapid Acting Insulin on Oxidative Stress in Patients with Type 2 Diabetes
    Naruse, Rika
    Takebayashi, Kohzo
    Aso, Yoshimasa
    Inukai, Toshihiko
    DIABETES, 2011, 60 : A291 - A291
  • [39] Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy
    A. Siebenhofer
    J. Plank
    A. Berghold
    K. Horvath
    P. T. Sawicki
    P. Beck
    T. R. Pieber
    Diabetologia, 2004, 47 : 1895 - 1905
  • [40] Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy
    Siebenhofer, A
    Plank, J
    Berghold, A
    Horvath, K
    Sawicki, PT
    Beck, P
    Pieber, TR
    DIABETOLOGIA, 2004, 47 (11) : 1895 - 1905